BioCryst Pharmaceuticals (MEX:BCRX) Cyclically Adjusted PB Ratio: (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BCRX BioCryst Pharmaceuticals Inc MEX:BCRX
55 GF Score
Price MXN182.00
GF Value MXN238.35
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCryst Pharmaceuticals  (MEX:BCRX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.71 57.70 902.39 0.00 0.00

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:BCRX vs SUPN, PBH, AMLX: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


MEX:BCRX
55GF Score
BioCryst Pharmaceuticals Inc MEX:BCRX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BioCryst Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, BioCryst Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-39.318/330.2130*330.2130
=-39.318

Current CPI (Mar. 2026) = 330.2130.

BioCryst Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.359 241.018 4.602
201609 1.047 241.428 1.432
201612 0.441 241.432 0.603
201703 9.026 243.801 12.225
201706 5.411 244.955 7.294
201709 18.562 246.819 24.834
201712 16.717 246.524 22.392
201803 11.422 249.554 15.114
201806 9.173 251.989 12.021
201809 12.434 252.439 16.265
201812 8.783 251.233 11.544
201903 3.959 254.202 5.143
201906 -1.600 256.143 -2.063
201909 -7.374 256.759 -9.484
201912 4.682 256.974 6.016
202003 0.555 258.115 0.710
202006 10.009 257.797 12.821
202009 4.208 260.280 5.339
202012 -2.166 260.474 -2.746
202103 -8.627 264.877 -10.755
202106 -11.814 271.696 -14.358
202109 -16.817 274.310 -20.244
202112 -11.905 278.802 -14.100
202203 -17.619 287.504 -20.236
202206 -23.079 296.311 -25.720
202209 -26.185 296.808 -29.132
202212 -30.566 296.797 -34.007
202303 -31.328 301.836 -34.273
202306 -35.168 305.109 -38.062
202309 -37.718 307.789 -40.466
202312 -37.577 306.746 -40.452
202403 -38.298 312.332 -40.491
202406 -42.168 314.175 -44.321
202409 -44.545 315.301 -46.652
202412 -47.597 315.605 -49.800
202503 -44.193 319.799 -45.632
202506 -37.818 322.561 -38.715
202509 -33.799 324.800 -34.362
202512 -10.070 324.054 -10.261
202603 -39.318 330.213 -39.318

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BioCryst Pharmaceuticals (MEX:BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of MXN182.00 is trading 23.6% below its estimated GF Value™ of MXN238.35. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:BCRX:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: MXN238.35 vs. price of MXN182.00 (23.6% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the MEX:BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:USABO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
55GF Score

Get the complete analysis for MEX:BCRX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN182.00
Price
MXN238.35
GF Value